MEDICAL supplies firm QT Vascular Ltd on Wednesday said the United States Patent and Trademark Office has issued allowance letters of four fundamental patents key to its unique portfolio of specialty balloons for the treatment of vascular disease in coronary and peripheral vessels.
The Catalist-listed firm said three of the patents cover the group's flagship platform, Chocolate®, while the fourth patent covers its Glider™ family of products.
Dr Eitan Konstantino, QT Vascular's CEO, said: "To receive four key patents allowances within a short span of time is truly an exceptional experience for a start-up company. We remain focused on the execution of our operational milestones and especially the drug coating programme."
QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, based in Pleasanton, California.